Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Medical Informatics

Date Submitted: Jul 4, 2025
Date Accepted: Nov 27, 2025

The final, peer-reviewed published version of this preprint can be found here:

An Intelligent Trial Eligibility Screening Tool Using Natural Language Processing With a Block-Based Visual Programming Interface: Development and Usability Study

Hu YH, Cheng YY, Lang CC, Su YH, Sung SF

An Intelligent Trial Eligibility Screening Tool Using Natural Language Processing With a Block-Based Visual Programming Interface: Development and Usability Study

JMIR Med Inform 2025;13:e80072

DOI: 10.2196/80072

PMID: 41380085

PMCID: 12698033

An Intelligent Trial Eligibility Screening Tool Using Natural Language Processing with a Block-Based Visual Programming Interface: Development and Usability Study

  • Ya-Han Hu; 
  • Yi-Ying Cheng; 
  • Chung-Ching Lang; 
  • Yu-Hsiang Su; 
  • Sheng-Feng Sung

ABSTRACT

Background:

Clinical trial eligibility screening using electronic medical records (EMRs) presents significant challenges due to the complexity and volume of patient data. Researchers must navigate through extensive documentation, interpret varied clinical terminologies, and manually extract relevant information. This time-consuming process often requires specialized knowledge and can lead to inconsistent participant selection, potentially compromising research outcomes and patient safety.

Objective:

This study assesses the effectiveness of the intelligent trial eligibility screening tool (iTEST), a clinical decision support tool powered by natural language processing (NLP), compared to standard EMR interfaces for eligibility screening.

Methods:

Twelve clinicians assessed four patients' eligibility for two clinical trials using both the standard EMR interface and iTEST. Primary outcomes included accuracy in determining eligibility. Secondary outcomes measured task completion time, cognitive workload using the National Aeronautics and Space Administration Task Load Index scale (NASA-TLX scale; range 0–100, with lower scores indicating a lower cognitive workload), and system usability through the System Usability Scale (SUS; range: 0–100, with higher scores indicating higher system usability).

Results:

The iTEST significantly improved accuracy scores (from 0.91 to 1.00, P <.001) and reduced completion time (from 3.18 to 2.44 minutes, P = .004) when compared to the standard EMR interface. Users reported lower cognitive workload (NASA-TLX scale, 39.7 vs. 62.8, P = .016) and higher SUS scores (71.3 vs. 46.3, P = .011) with iTEST. Particularly notable improvements in perceived cognitive workload were observed in temporal demand, effort, and frustration levels.

Conclusions:

The iTEST performed superior to standard EMR interfaces in the eligibility screening process, delivering improved accuracy, reduced task completion time, and lower cognitive workload. These findings indicate that NLP-powered tools can enhance the efficiency and reliability of clinical trial participant selection while alleviating clinician burdens.


 Citation

Please cite as:

Hu YH, Cheng YY, Lang CC, Su YH, Sung SF

An Intelligent Trial Eligibility Screening Tool Using Natural Language Processing With a Block-Based Visual Programming Interface: Development and Usability Study

JMIR Med Inform 2025;13:e80072

DOI: 10.2196/80072

PMID: 41380085

PMCID: 12698033

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.